ASMB — Assembly Biosciences Share Price
0.000.00%
Last trade - 00:00- $108.30m
- -$3.78m
- $28.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.25 | ||
| Price to Tang. Book | 3.25 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.64% | ||
| Return on Equity | -107.92% | ||
| Operating Margin | -159.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 79.11 | 6.25 | n/a | 7.16 | 28.52 | 30.98 | 24.38 | 12.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Directors
- William Ringo NEC (75)
- John McHutchison PRE (63)
- Michael Samar CFO (49)
- Jason Okazaki COO (45)
- Nicole White SVP
- William Delaney CSO (49)
- Luisa Stamm OTH (45)
- Lisa Johnson-pratt DRC (57)
- Anthony Altig IND (65)
- Gina Consylman IND (49)
- Richard DiMarchi IND (68)
- Myron Holubiak IND (74)
- Michael Houghton IND (64)
- Susan Mahony IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2005
- Public Since
- December 17th, 2010
- No. of Shareholders
- 49
- No. of Employees
- 73
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 7,637,553
- Address
- Two Tower Place, 7Th Floor, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.assemblybio.com/
- Phone
- +1 2125544388
- Auditors
- Ernst & Young LLP
Upcoming Events for ASMB
Assembly Biosciences Inc Annual Shareholders Meeting
Assembly Biosciences Inc Annual Shareholders Meeting
Q2 2025 Assembly Biosciences Inc Earnings Release
Similar to ASMB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Assembly Biosciences share price?
As of Today at 19:23 UTC, shares in Assembly Biosciences are trading at $14.18. This share price information is delayed by 15 minutes.
How has the Assembly Biosciences share price performed this year?
Shares in Assembly Biosciences last closed at $14.18 and the price had moved by +10.69% over the past 365 days. In terms of relative price strength the Assembly Biosciences share price has underperformed the S&P500 Index by -0.18% over the past year.
What are the analyst and broker recommendations for Assembly Biosciences?
The overall consensus recommendation for Assembly Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Assembly Biosciences dividend yield?
Assembly Biosciences does not currently pay a dividend.
Does Assembly Biosciences pay a dividend?
Assembly Biosciences does not currently pay a dividend.
When does Assembly Biosciences next pay dividends?
Assembly Biosciences does not currently pay a dividend.
How do I buy Assembly Biosciences shares?
To buy shares in Assembly Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Assembly Biosciences?
As of the previous close price of $14.18, shares in Assembly Biosciences had a market capitalisation of $108.30m.
Where are Assembly Biosciences shares listed?
Here are the trading details for Assembly Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ASMB
What kind of share is Assembly Biosciences?
Based on an overall assessment of its quality, value and momentum Assembly Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Assembly Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Assembly Biosciences is $34.00. That is 139.77% above the last closing price of $14.18.
Analysts covering Assembly Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$5.68 for the next financial year.
Find out moreWhat is the trend in the Assembly Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Assembly Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -15.66%.
As of the last closing price of $14.18, shares in Assembly Biosciences were trading -1.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Assembly Biosciences PE Ratio?
The Assembly Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Assembly Biosciences?
Assembly Biosciences' management team is headed by:
- William Ringo - NEC
- John McHutchison - PRE
- Michael Samar - CFO
- Jason Okazaki - COO
- Nicole White - SVP
- William Delaney - CSO
- Luisa Stamm - OTH
- Lisa Johnson-pratt - DRC
- Anthony Altig - IND
- Gina Consylman - IND
- Richard DiMarchi - IND
- Myron Holubiak - IND
- Michael Houghton - IND
- Susan Mahony - IND